We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Lab-on-a-Chip Technology Demonstrated in Small Diagnostic Device

By Labmedica staff writers
Posted on 04 Apr 2007
Print article
A high sensitivity, small medical diagnostic device was developed using lab-on-a-chip technology. The device can measure biomarkers with high sensitivity and at low cost.

The technology uses semiconductor films located on either side of a microfluidics chip. One film illuminates the chip, where appropriate, while the other film detects an output signal, which is fed to a display. The device used two forms of detection utilizing chemiluminescence and fluorescence to detect different markers of interest.

Developed by Acrongenomics (Geneva, Switzerland) and Molecular Vision (London, UK) this technology is capable of further miniaturization along with large scale, low cost manufacturing, which will bring forward disposable, point-of-care diagnostics for a large range of biomarkers. The companies presented possible design concepts of their BioLED Lab-on-a-Chip technology applications to be used at home, in doctor's offices, and hospitals.

Molecular Vision is a spin-out company of Imperial Innovations Ltd, and was founded in order to meet a clearly defined demand in the medical diagnostics, biosensors, and analytic instrumentations markets: the need for miniaturized chemical and biologic detectors offering high sensitivity and functionality at low cost. The company has directly addressed this market demand by inventing a novel method for optical detection based on recent advances in organic electronics and light-emitting diodes combined with microfluidics technology. The company has mainly focused on applying its technology to the medical diagnostics markets. Molecular Vision recently signed a major development contract with Acrongenomics, Inc., to jointly exploit and commercialize the technology.

Acrongenomics Inc. is a publicly traded company that focuses on investing in and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications.


Related Links:
Acrongenomics
Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Chemistry Analyzer
MS100
New
Nuclear Matrix Protein 22 Test
NMP22 Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.